3D printing allows more precise drug packaging and dosing which is a step further towards the future of personalized drugs. The aim of this research is to produce 3D-printed tablets using prepared filaments containing dronedarone hydrochloride. The filaments were prepared using a NoztekPro extruder as part of the graduate thesis of student Monika Leskovar. Eleven different filaments were prepared at three different temperatures (150 ℃, 160 ℃, 170 ℃) and using three different poly(vinyl-alcohol) filaments (PVA Technology Outlet, PVA Formfutura, PVA Formfutura Atlas). The filaments were prepared by using poly(vinyl-alcohol), poly(ethylene-glycol) and dronedarone hydrochloride. Two formulations were prepared containing 10% and 20% of dronedarone. The obtained filaments were used for 3D printing of tablets and test tubes by Fused Deposition Modeling technique. Release profiles of dronedarone from manufactured tablets were obtained using in vitro tests. A tensile test for the tubes was also performed. The results showed that the total concentration of dronedarone released from all three poly(vinyl-alcohol) samples was largest at the highest temperature (170 ℃). Dronedarone hydrochloride release profiles were approximated by parameters of selected kinetic models. PVA Formfutura and PVA Formfutura Atlas are highly elastic with certain material strength. This research shows that by choosing the appropriate process conditions and composition of polymer blends, filaments for printing of personalized tablets can be prepared.